TIMES
KEEP UP WITH THE When time is all
that matters–
THERE’S NO TIME FOR ERROR AND NO TIME TO WASTE IN A MALIGNANT HYPERTHERMIA (MH) CRISIS.
Every delay in the treatment of MH can increase the risk of further complications.1
Older, lower-concentration dantrolene sodium formulations
are time consuming to reconstitute and administer.2 Conversely, for a 2.5 mg/kg loading dose, RYANODEX® only requires 1 vial that can be
reconstituted and administered by 1 healthcare professional in 1 minute.3-6 Since RYANODEX®
risk of complications due to treatment delays.1,2,4,5 Get RYANODEX®
or call 855.318.2170.
References: 1. Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg. 2014;118(2):381-387. 2. Brandom BW. Cases from the North American MH Registry/MHAUS [1992 through 2012]. 3. Reed A, Yudkowitz F. Clinical Cases in Anesthesia. 4th ed. Philadelphia, PA: Saunders/Elsevier; 2014. 4. Data on fi le. Eagle Pharmaceuticals, Inc. 5. RYANODEX [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2014. 6. Malignant Hyperthermia Association of the United States website. Managing an MH crisis.
http://www.mhaus.org/ healthcareprofessionals/managing-a-crisis. Accessed May 27, 2014.
Please see Brief Summary of full Prescribing Information on the following page.
© 2015 Eagle Pharmaceuticals, Inc. All rights reserved. Woodcliff Lake, NJ RYN15-0011-01 7/2015
is fast to reconstitute and administer, it could reduce the for your institution today. Visit
RYANODEX.com/asca
INDICATION RYANODEX®
(dantrolene sodium) for injectable
suspension is indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.
IMPORTANT SAFETY INFORMATION RYANODEX®
• Discontinuing triggering anesthetic agents
• Increasing oxygen
• Managing the metabolic acidosis
is not a substitute for appropriate supportive
measures in the treatment of malignant hyperthermia (MH), including:
• Instituting cooling when necessary
• Administering diuretics to prevent late kidney injury due to myoglobinuria (the amount of mannitol in RYANODEX®
is insuffi cient to maintain diuresis)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42
